The neurobiological bases for the pharmacotherapy of nicotine addiction

Current Pharmaceutical Design

Volumn 13, Issue 12, 2007, Pages 1269-1284

  Di Matteo, Vincenzo ^a,b   Pierucci, Massimo ^a,b   Di Giovanni, Giuseppe ^a,b   Benigno, Arcangelo ^a,b   Esposito, Ennio ^a,b  

^a Instituto di Recerche Farmacologiche Mario Negri   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

5 HT release; Dorsal raphe nucleus; Fos like immunoreactivity; GABAergic input; nACh receptor subtypes

Indexed keywords

1,1 DIMETHYL 4 PHENYLPIPERAZINIUM; 1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL] 6 TRIFLUOROMETHYLINDOLINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; AMFEBUTAMONE; CLONIDINE; DOPAMINE; DOXEPIN; FLUOXETINE; LOBELINE; MECAMYLAMINE; MOCLOBEMIDE; NALTREXONE; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NORTRIPTYLINE; PLACEBO; SEROTONIN 2C ANTAGONIST; UNCLASSIFIED DRUG; VARENICLINE; YOHIMBINE;

ANIMAL BEHAVIOR; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERACTIVITY; INSOMNIA; MESOLIMBIC DOPAMINERGIC SYSTEM; NERVE CELL STIMULATION; NERVOUSNESS; NICOTINE REPLACEMENT THERAPY; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SUBSTANTIA NIGRA; TOBACCO DEPENDENCE; VENTRAL TEGMENTUM; XEROSTOMIA;

ANIMALS; ANTIDEPRESSIVE AGENTS; HUMANS; NICOTINE; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; RECEPTORS, NICOTINIC; TOBACCO USE DISORDER;

EID: 34248326492     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780618920     Document Type: Review

References (234)

1. WHO. Neuroscience of psychoactive substance use and dependence. World Health Organization 2004; World Health Organization.
2. Rigotti NA. Treatment of tobacco use and dependence. N Engl J Med 2002; 346: 506-512.
3. Kendler KS, Bulik CM, Silberg J, Hettema JM, Myers J, Prescott CA. Childhood sexual abuse and adult psychiatric and substance use disorders in women: An epidemiological and cotwin control analysis. Arch Gen Psychiatry 2000; 57: 953-959.
4. Tsuang MT, Lyons MJ, Eisen SA, Goldberg J, True W, Lin W, et al. Genetic influences on DMS-III-R drug abuse and dependence: A study of 3,372 twin pairs. Am J Med Genet 1996; 67: 473-477.
5. Nestler EJ. From neurobiology to treatment: Progress against addiction. Nat Neurosci 2002; 5 (Suppl): 1076-1079.
6. Berke JD, Hyman SE. Addiction, dopamine, and the molecular mechanisms of memory. Neuron 2000; 25: 515-532.
7. Di Chiara G. A motivational learning hypothesis of the role of mesolimbic dopamine in compulsive drug use. J Psychopharmacol 1998; 12: 54-67.
8. Robinson TE, Berridge KC. The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction 2000; 95 (Suppl 2): S91-S117.
9. Kreek MJ, LaForge KS, Butelman E. Pharmacotherapy of addictions. Nat Rev Drug Discov 2002; 1: 710-726.
10. White NM. Reward and reinforcement: What's the difference? Neurosci Biobehav Rev 1989; 13: 181-186.
11. Gawin FH, Kleber HD. Abstinence symptomatology and psychiatric diagnoses in cocaine abusers: Clinical observations. Arch Gen Psychiatry 1986; 43: 107-113.
12. Kalivas PW, Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Brain Res Rev 1991; 16: 223-244.
13. Volkow ND, Fowler JS, Wang G. Role orMopamine in drug reinforcement and addiction; results from imaging studies. Behav Pharmacol 2002; 13: 355-366.
14. Brown F. The cocaine threat. MCN Am J Matern Child Nurs 1989; 14: 308.
15. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug Dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes. JAMA 2000; 284: 1689-1695.
16. O'Brien CP, Childress AR, Ehrman R, Robbins SJ. Conditioning factors in drug abuse: Can they explain compulsion? J Psychopharmacol 1998; 12: 15-22.
17. Jain A. Treating nicotine addiction. Br Med J 2003; 327: 1394-1395.
18. Benowitz NL, Peng MW. Non-nicotinic pharmacotherapy for smoking cessation. CNS Drugs 2000; 13: 265-285.
19. Reavill C, Stolerman IP. Locomotor activity to rats after administration of nicotinic agonists intracerebrally. Br J Pharmacol 1990; 99: 273-278.
20. Corrigall WA, Coen KM. Selective dopamine antagonists reduce nicotine self-administration. Psychopharmacology 1991; 104: 171-176.
21. Rose JE, Corrigall WA. Nicotine self-administration in animals and humans: Similarities and differences. Psychopharmacology 1997; 130: 28-40.
22. Olausson P, Engel JA, Söderpalm B. Behavioral sensitization to nicotine is associated with behavioral disinhibition: Counteraction by citalopram. Psychopharmacology 1999; 142: 111-119.
23. Laviolette SR, van der Kooy D. Blockade of mesolimbic dopamine transmission dramatically increases sensitivity to the rewarding effects of nicotine in the ventral tegmental area. Mol Psychiatry 2003; 8: 50-59.
24. Clarke PBS, Fu DS, Jakubovic A, Fibiger HC. Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in rats. J Pharmacol Exp Ther 1988; 246: 701-708.
25. Corrigall WA, Franklin KB, Coen KM, Clarke PBS. The mesolimbic dopamine system is implicated in the reinforcing effects of nicotine. Psychopharmacology 1992; 107: 285-89.
26. Corrigall WA, Coen KM, Adamson KL. Self-administered nicotine activates the mesolimbic dopaminergic system through the ventral tegmental area. Brain Res 1994; 653: 278-284.
27. Louis M, Clarke PB. Effect of ventral tegmental 6-hydroxydopamine lesions on the locomotor stimulant action of nicotine in rats. Neuropharmacology 1998; 37: 1503-1513.
28. Dani JA, De Biasi M. Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 2001; 70: 439-446.
29. Damsma G, Day J, Fibiger HC. Lack of tolerance to nicotine-induced dopamine release in the nucleus accumbens. Eur J Pharmacol 1989; 168: 363-368.
30. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988; 85: 5274-5278.
31. Brazell MP, Mitchell SN, Joseph MH, Gray JA. Acute administration of nicotine increases the in vivo extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid and ascorbic acid preferentially in the nucleus accumbens of the rat: Comparison with caudate-putamen. Neuropharmacology 1990; 29: 1177-1185.
32. Nisell M, Nomikos GG, Svensson TH. Infusion or nicotine in the ventral tegmental area or the nucleus accumbens of the rat differentially affects accumbal dopamine release. Pharmacol Toxicol 1994; 75: 348-452.
33. Pontieri FE, Tanda G, Orzi F, Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996; 382: 255-257.
34. Marshall DL, Redfern PH, Wonnacott S. Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: Comparison of naive and chronic nicotine-treated rats. J Neurochem 1997; 68: 1511-1519.
35. Maisonneuve IM, Mann GL, Deibel CR, Glick SD. Ibogaine and the dopaminergic response to nicotine. Psychopharmacology 1997; 129: 249-256.
36. Balfour DJ, Benwell ME, Birrell CE, Kelly RJ, Al-Aloul M. Sensitization of the mesoaccumbens dopamine response to nicotine. Pharmacol Biochem Behav 1998; 59, 1021-1030.
37. Imperato A, Mulas A, Di Chiara G. Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol 1986; 132: 337-338.
38. Toth E, Sershen H, Hashim A, Vizi ES, Lajtha A. Effect of nicotine on extracellular levels of neurotransmitters assessed by microdialysis in various brain regions: Role of glutamic; acid. Neurochem Res 1992; 17: 265-271.
39. Lichtensteiger W, Hefti F, Felix D, Huwyler T, Melamed E, Sclumpf M. Stimulation of nigrostriatal dopamine neurones by nicotine. Neuropharmacology 1982; 21: 963-968.
40. Clarke PBS, Hommer DW, Pert A, Skirboll LR. Electrophysiological actions of nicotine on substantia nigra single units. Br J Pharmacol 1985; 85: 827-835.
41. Grenhoff J, Aston-Jones G, Svensson TH. Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta Physiol Scand 1986; 128: 351-358.
42. Mereu G, Yoon KWP, Boi V, Gessa GL, Naes L, Westfall TC. Preferential stimulation of ventral tegmental area dopaminergic neurons by nicotine. Eur J Pharmacol 1987; 141: 395-99.
43. Calabresi P, Lacey MG, North RA. Nicotinic excitation of rat ventral tegmental neurones in vitro studied by intracellular recording. Br J Pharmacol 1989; 98: 135-140.
44. Nisell M, Nomikos GG, Svensson TH. Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse 1994; 16: 36-44.
45. Pidoplichko VI, DeBiasi M, Williams JT, Dani J-A. Nicotine activates and desensitizes midbrain dopamine neurons. Nature 1997; 390: 401-404.
46. Schilström B, Svensson HM, Svensson TH, Nomikos GG. Nicotine and food induced dopamine release in the nucleus accumbens of the rat: Putative role of α7 nicotinic receptors in the ventral tegmental area. Neuroscience 1998; 85: 1005-1009.
47. Sorenson EM, Shiroyama T, Kitai ST. Postsynaptic nicotinic receptors on dopaminergic neurons in the substantia nigra pars compacta, of the rat. Neuroscience 1998; 87: 659-673.
48. Mifsud J-C, Hernandez L, Hoebel BG. Nicotine infused into the nucleus accumbens increases synaptic dopamine as measured by in vivo microdialysis. Brain Res 1989; 478: 365-367.
49. Rowell PP, Hillebrand JA. Characterization of nicotine-induced desensitization of evoked dopamine release from rat striatal synaptosomes. J Neurochem 1994; 63: 561-69.
50. Ferrari R, Le Novére N, Picciotto MR, Changeux JP, Zoli M. Acute and long-term changes in the mesolimbic dopamine pathway after systemic or local single nicotine injections. Eur J Neurosci 2002; 15: 1810-1818.
51. a Stein EA, Pankiewicz J, Harsch HH, Cho J-K, Fuller SA, Hoffman RG, et al. Nicotine-induced limbic cortical activation in the human brain: A functional MRI study. Am J Psychiatry 1998; 155: 1009-1015
52. b Pidoplichko VI, Noguchi J, Arcola OO, Liang Y, Peterson J, Zhang T, et al. Nicotinic cholinergic synaptic mechanisms in the ventral tegmental area contribute to nicotine addiction. Learn Mem 2004; 11: 60-69.
53. Clarke PBS, Pert A. Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons. Brain Res 1985; 348: 355-358.
54. Sargent PB. The diversity of neuronal nicotinic acetylcholine receptors. Annnu Rev Neurosci 1993; 16: 403-443.
55. McGehee DS, Role LW. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu Rev Physiol 1995; 57: 521-546.
56. Le Novére N, Zoli M, Changeux J-P. Neuronal nicotinic receptor α6 subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain. Eur J Neurosci 1996; 8: 2428-2439.
57. Charpantier E, Barnéoud P, Moser P, Besnard F, Sgard F. Nicotinic acetylcholine subunit mRNA expression in dopaminergic neurons of the rat substantia nigra and ventral tegmental area. Neuroreport 1998; 9: 3097-3101.
58. Klink R, de Kerkhove d'Exaerde A, Zoli M, Changeux J-P. Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. J Neurosci 2001; 21: 1452-1463.
59. Serova L, Sabban EL. Involvement of α7 nicotinic acetylcholine receptors in gene expression of dopamine biosynthetic enzymes in rat brain. J Pharmacol Exp Ther 2002; 303: 896-903.
60. Benwell ME, Balfour DJ. The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity. Br J Pharmacol 1992; 105: 849-856.
61. Shim I, Javaid JI, Wirtshafter D, Jang SY, Shin KH, Lee HJ, et al. Nicotine-induced behavioral sensitization is associated with extracellular dopamine release and expression of c-Fos in the striatum and nucleus accumbens of the rat. Behav Brain Res 2001; 121: 137-147
62. 2c receptors reduces the locomotor and rewarding effects of nicotine. Psychopharmacology 2001; 157: 292-298.
63. Schoffelmeer ANM, De Vries U, Wardeh G, van der Ven HWM, Vanderschuren LJMJ. Psychostimulant-induced behavioral sensitization depends on nicotinic receptor activation. J Neurosci 2002; 22: 3269-3276.
64. Vanderschuren LJMJ, Schmidt ED, De Vries TJ, Van Moorsel CAP, Tilders FJH, Schoffelmeer ANM. A single exposure to amphetamine is sufficient to induce long-term behavioral, neuroendocrine, and neurochemical sensitization in rats. J Neurosci 1999; 19: 9579-9586.
65. White FJ, Kalivas PW. Neuroadaptations involved in amphetamine and cocaine addiction. Drug Alchool Depend 1998; 51: 141-153.
66. Cadoni C, Di Chiara G. Differential changes in accumbens shell and core dopamine in behavioral sensitization to nicotine. Eur J Pharmacol 2000; 387: R23-R25.
67. Marks MJ, Pauly JR, Gross SD, Deneris ES, Hemans-Borgmeyer I, Heinemann SF, et al. Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment. J Neurosci 1992; 12: 2765-2784.
68. Dani JA, Heinemann S. Molecular and cellular aspects of nicotine abuse. Neuron 1996; 16: 905-908.
69. Buisson B, Bertrand D. Chronic exposure to nicotine upregulates the human α4β2 nicotinic acetylcholine receptor function. J Neurosci 2001; 21: 1819-1829.
70. Unwin N. Structure and action of the acetylcholine receptor explored by electron microscopy. FEBS Left 2003; 555: 91-95.
71. Dajas-Bailador F, Wonnacott S. Nicotinic acetyrcholine receptors and the regulation of neuronal signalling. Trends Pharmacol Sci 2004; 25: 317-324.
72. Wonnacott S, Sidhpura N, Balfour DJK. Nicotine: From molecular mechanisms to behaviour. Curr Opin Pharmacol 2005; 5: 53-59.
73. 2+ permeability of nicotinic acetylcholine receptors. Cell Calcium 2004; 35: 1-8.
74. 2+ modulation of human neuronal α3 nicotinic receptors. J Pharmacol Exp Ther 1998; 286: 311-320.
75. 2+ current through human neuronal α7 nicotinic acetylcholine receptors. Cell Calcium 2003; 34: 205-259.
76. Burnashev N, Zhou Z, Neher E, Sakman B. Fractional calcium currents through recombinant GluR channels of the NMDA, AMPA and kainate receptor subtypes. J Physiol 1995; 485: 403-418.
77. 2+ permeability in recombinant glutamate receptor subtypes. J Physiol 2002; 538: 25-39.
78. Rathouz MM, Berg DK. Synaptic-type acetylcholine receptors raise intracellular calcium levels in neurons by two mechanisms. J Neurosci 1994; 14: 6935-6945.
79. 2+ stores. J Neurochem 2002; 81: 606-614.
80. Mulle C, Lena C, Changeux JP. Potentiation of nicotinic receptor response by external calcium in rat central neurons. Neuron 1992; 8: 937-945.
81. Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: Dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol 2003; 4: 517-529
82. Brain KL, Trout SJ, Jackson VM, Dass N, Cunnane TC. Nicotine induces calcium spikes in single nerve terminal varicosities: A role for intracellular calcium stores. Neuroscience 2001; 106: 395-403.
83. Tsuneki H, Klink R, Léna C, Korn H, Changeux JP. Calcium mobilization elicited by two types of nicotinic acetylcholine receptors in mouse substantia nigra pars compacta. Eur J Neurosci 2000; 12: 2475-2485.
84. Shoop RD, Chang KT, Ellisman MH, Berg DK. Synaptically driven calcium transients via nicotinic receptors on somatic spines. J Neurosci 2001; 21: 771-781.
85. 2+ in rat intracardiac ganglion neurons. J Neurophysiol 2003; 90: 1956-1964.
86. Wooltorton JR, Pidoplichko VI, Broide RS, Dani JA. Differential desensitization and distribution of nicotinic acetylcholine receptor subtypes in midbrain dopamine areas. J Neurosci 2003; 23: 3176-3185
87. Mansvelder HD, McGehee DS. Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron 2000; 27: 349-357.
88. Mansvelder HD, Keath JR, McGehee DS. Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron 2002; 33: 905-919.
89. Champtiaux N, Gotti C, Cordero-Erausquin M, David DJ, Przybylski C, Léna C, et al. Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. J Neurosci 2003; 23: 7820-7819.
90. Salminen O, Murphy KL, McIntosh JM, Drago J, Marks MJ, Collins AC, et al. Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol Pharmacol 2004; 65: 1526-1535.
91. Partridge JG, Apparsundaram S, Gerhardt GA, Ronesi J, Lovinger DM. Nicotinic acetylcholine receptors interact with dopamine in induction of striatal long-term depression. J Neurosci 2002; 22: 2541-2549.
92. Picciotto MR, Zoli M, Rimondini R, Léna C, Marubio LM, Pich EM, et al. Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature 1998; 391:173-177
93. 3H]dopamine release from mouse striatal synaptosomes. J Neurochem 1994; 62: 1390-1398.
94. Schilström B, De Villiers S, Svensson TH, Nomikos GG. Nicotine-induced Fos expression in the nucleus accumbens and the prefrontal cortex of the rat: Role of nicotinic and NMDA receptors in the ventral tegmental area. Synapse 2000; 36: 314-321.
95. 2C receptors blocks the enhancement of striatal and accumbal dopamine release induced by nicotine administration. J Neurochem 2004; 89: 418-429.
96. Balfour DJ, Wright AE, Benwell ME, Birrell CE. The putative role of extra-synaptic mesolimbic dopamine in the neurobiology of nicotine dependence. Behav Brain Res 2000; 113: 73-83.
97. Iyaniwura TT, Wright AE, Balfour DJK. Evidence that mesoaccumbens dopamine and locomotor responses to nicotine in the rat are influenced by pretreatment dose and strain. Psychopharmacology 2001; 158: 73-79.
98. Robinson TE, Berridge KC. Incentive-sensitization and addiction. Addiction 2001; 96:103-114.
99. Serova L, Danailov E, Chamas F. Sabban EL. Nicotine infusion modulates immobilization stress-triggered induction of gene expression of rat catecholamine biosynthetic enzymes. J Pharmacol Exp Ther 1999; 291: 884-892.
100. Brunzell DH, Russell DS, Picciotto MR. In vivo nicotine treatment regulates mesocorticolimbic CREB and ERK signalling in C57B1/6J mice. J Neurochem 2003; 84: 1431-1441.
101. Olausson P, Jentsch DJ, Taylor JR. Repeated nicotine exposure enhances responding with conditioned reinforcement. Psychopharmacology 2004; 173: 98-104.
102. Rice ME, Cragg SJ. Nicotine amplifies reward-related dopamine signals in striatum. Nat Neurosci 2004; 7: 583-584.
103. 2C receptors blocks the hyperactivation of midbrain dopamine neurons induced by nicotine administration. J Pharmacol Exp Ther 2004; 309: 109-118.
104. Benowitz NL. Pharmacology of nicotine: Addiction and therapeutics. Annu Rev Pharmacol Toxicol 1996; 36: 597-613.
105. George TP, O'Malley SS. Current pharmacological treatments for nicotine dependence. Trends Pharmacol Sci 2004; 25: 42-48.
106. Jones BJ, Blackburn TP. The medical benefit of 5-HT research. Pharmacol Biochem Behav 2002; 71: 555-568.
107. Borrelli B, Niaura R, Keuthen NJ, Goldstein MG, DePue JD, Murphy C, et al. Development of major depressive disorder during smoking-cessation. J Clin Psychiatry 1996; 57: 534-538.
108. Glassman AH. Cigarette smoking: Implications for psychiatric illness. Am J Psychiatry 1993; 150: 546-553.
109. Vazquez-Palacios G, Jaime-Bonilla H, Velazquez-Moctezuma J. Antidepressant-like effects of the acute and chronic administration of nicotine in the rat forced swimming test and its interaction with fluoxetine. Pharmacol Biochem Behav 2004; 78: 165-169.
110. Leonard S, Adler LE, Benhammou K, Berger R, Breese CR, Drebing C, et al. Smoking and mental illness. Pharmacol Biochem Behav 2001; 70: 561-570.
111. Covey LS, Glassman AH, Stetner F. Major depression following smoking cessation. Am J Psychiatry 1997; 154: 263-265.
112. Prochazka AV, Weaver MJ, Keller RT, Fryer GE, Licari PA, Lofaso D. A randomized trial of nortriptyline for smoking cessation. Arch Intern Med 1998; 158: 2035-2039.
113. Hall SM, Reus VI, Munoz RF, Sees KL, Humfleet G, Hartz DT, et al. Nortriptyline and cognitive-behavioral tharapy in the treatment of cigarette smoking. Arch Gen Psychiatry 1998; 55: 683-690.
114. Holm KJ, Spencer CM. Bupropion: A review of its use in the management of smoking cessation. Drugs 2000; 59: 1007-102.
115. Glassman AH, Helzer JE, Covey LS, Cottler LB, Stetner F, Tipp JE, et al. Smoking, smoking cessation, and major depression. J Am Med Assoc 1990; 264: 1546-1549.
116. Greeman M, McClellan TA. Negative effects of a smoking ban on an inpatient psychiatry service. Hosp Community Psychiatry 1991; 42: 408-412.
117. Dalack GW, Becks L, Hill E, Pomerleau OF, Meador-Woodruff JH. Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia. Neuropsychopharmacology 1999; 21: 195-202.
118. Grottick AJ, Wyler R, Higgins GA. The α4β4 agonist SIB 1765F, but not the α7 agonist AR-R 17779, cross-sensitises to the psychostimulant effects of nicotine. Psychopharmacology 2000; 150: 233-236.
119. Epping-Jordan MP, Picciotto MR, Changeux JP, Merlo-Pich E. Assessment of nicotinic receptor subunit contributions to nicotine self-administration in mutant mice. Psychopharmacology 1999; 147: 25-26.
120. Maskos U, Molles BE, Pons S, Besson M, Guiard BP, Guilloux J-P, et al. Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature 2005; 436: 103-107.
121. Prisco S, Pagannone S, Esposito E. Serotonin-dopamine interaction in the rat ventral tegmental area: An electrophysiological study in vivo. J Pharmacol Exp Ther 1994; 271: 83-90.
122. 2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: A combined in vivo electrophysiological and microdialysis study. Neuroscience 1999; 91: 587-597.
123. 2C receptors in the control of central dopamine function. Trends Pharmacol Sci 2001; 22: 229-232.
124. 2B receptor antagonist with anxiolytic-like properties. Br J Pharmacol 1996; 117: 427-434.
125. 2C receptor antagonist. Neuropharmacology 1997; 36: 609-620.
126. 2C/2B receptors enhances dopamine release in the rat nucleus accumbens. Neuropharmacology 1998; 37: 265-272.
127. 2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacology 1999; 38: 1195-1205.
128. Millan MJ, Dekeyne A, Gobert A. Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology 1998; 37: 953-955.
129. 2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat. Synapse 2000; 36: 205-221.
130. 2C agonists: Pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 1998; 286: 913-924.
131. 2C receptors. Brain Res 2000; 865: 85-90.
132. 2C/2B receptor antagonists: Neurochemical and behavioural studies. Neuropharmacology 2000; 39: 2318-2328.
133. 2C) receptors in the ventrotegmental area inhibits stress-induced but not basal dopamine release in the rat prefrontal cortex. J Neurochem 2002; 82: 93-100.
134. 4 receptors selectively regulate the impulse-dependent exocytosis of dopamine in the rat striatum: in vivo studies with morphine, amphetamine and cocaine. Neuropharmacology 2002; 43: 1099-1110
135. 2C agonists selectively inhibit morphine-induced dopamine efflux in the nucleus accumbens. Brain Res 1998; 781: 291-299.
136. 2C receptors on cocaine- and food-maintained behavior. J Pharmacol Exp Ther 2000; 295: 1183-1191.
137. 2C receptors in modifying ethanol self-administration behaviour. Pharmacol Biochem Behav 2002; 71: 735-744.
138. 2C receptor inverse agonists: Identification of 5-methyl-l-({2- [(2-methyl-3-pyridyl)oxy]-5-pyridyl}carbamoyl -6-trifluoromethyl- indoline (SB 243213) as a potential antidepressant/anxiolytic agent. J Med Chem 2000; 43: 1123-1134.
139. Seth P, Cheeta S, Tucci S, File SE. Nicotinic-serotonergic interactions in brain and behaviour. Pharmacol Biochem Behav 2002; 71: 795-805.
140. Mihailescu S, Palomero-Rivero M, Maede-Huerta P, Maza-Flores A, Drucker-Colin R. Effects of nicotine and mecamylamine on rat dorsal raphé neurons. Eur J Pharmacol 1989; 167: 311-322.
141. Ribeiro EB, Bettiker RL, Bogdanov M, Wurtman RJ. Effects of systemic nicotine on serotonin release in rat brain. Brain Res 1993; 621: 311-318.
142. 3H]5-hydroxytryptamine release from rat striatal synaptosonies. Neuropharmacology 2000; 39: 290-299
143. Fuxe K, Everitt BJ, Hokfelt T. On the action of nicotine and cotinine on central 5-hydroxytryptamine neurons. Pharmacol Biochem Behav 1979; 10: 671-677.
144. Balfour DJ, Graham CA, Vale AL. Studies on the possible role of brain 5-HT systems and adrenocortical activity in behavioural responses to nicotine and diazepam in an elevated X-maze. Psychopharmacology 1986; 90: 528-532.
145. Balfour DJ, Ridley DL. The effects of nicotine on neural pathways implicated in depression: A factor in nicotine addiction? Pharmacol Biochem Behav 2000; 66: 79-85.
146. Benwell ME, Balfour DJ. Effects of nicotine administration and its withdrawal on plasma corticosterone and brain 5-hydroxyindoles. Psychopharmacology 1979; 63: 7-11.
147. Benwell ME, Balfour DJ, Anderson JM. Smoking-associated changes in the serotonergic systems of discrete regions of human brain. Psychopharmacology 1990; 102: 68-72.
148. 2 receptors. Naunyn-Schmiedeberg's Arch. Pharmacol 2002; 366: 276-281
149. 2 receptor agonists on the behavioral and neurochemical consequences of repeated nicotine treatment. Eur J Pharmacol 2001; 420: 45-54.
150. Olausson P, Engel JA, Söderpalm B. Involvement of serotonin in nicotine dependence: Processes relevant to positive and negative regulation of drug intake. Pharmacol Biochem Behav 2002; 71: 757-771
151. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685-691.
152. Dong J, Blier P. Modification of norepinephrine and serotonin, but not dopamine, neuron firing rate by sustained bupropion treatment. Psychopharmacology 2001; 155: 52-57.
153. Dewey SL, Brodie JD, Gerasimov M, Horan B, Gardner EL, Ashby CR Jr. A pharmacologic strategy for the treatment of nicotine addiction. Synapse 1999, 31: 76-86.
154. Corrigall WA, Coen KM, Adamson KL, Chow BLC, Zhang J. Response of nicotine self-administration in the rat to manipulations of mu-opioid and γ-aminobutyric acid receptors in the ventral tegmental area. Psychopharmacology 2000; 149: 107-114.
155. Summers KL, Lippiello P, Giacobini E. A microdialysis study of the effects of the nicotinic agonist RJR-2403 on cortical release of acetylcholine and biogenic amines. Neurochem Res 1996; 21: 1181-1186
156. 3H]acetylcholine on catecholamine and serotonin axons in brain. J Neurochem 1984; 42: 1495-1498.
157. Yu ZJ, Wecker L. Chronic nicotine administration differentially affects neurotransmitter release from rat striatal slices. J Neurochem 1994; 63: 186-194.
158. Takahashi H, Takada Y, Nagai N, Urano T, Takada A. Nicotine increases stress-induced serotonin release by stimulating nicotinic acetylcholine receptor in rat striatum. Synapse 1998; 28: 212-219.
159. 3H]5-HT from rat hippocampal slices. Neuropharmacology 1996; 35: 1769-1777.
160. Kenny PJ, File SE, Neal MJ. Eviden a complex influence of nicotinic acetylcholine receptors on hippocampal serotonin release. J Neurochem 2000; 75: 2409-2414.
161. Ridley DL, Balfour DJK. The influence of nicotine on 5-HT overflow in the dorsal hippocampus of the rat. Br J Pharmacol 1997; 122: 301P.
162. Takada Y, Urano T, Ihara H, Takada A. Changes in the central and peripheral serotonergic system in rats exposed to water-immersion restrained stress and nicotine administration. Neurosci Res 1995; 23: 305-311.
163. Engberg G, Erhardt S, Sharp T, Hajós M. Nicotine inhibits firing activity of dorsal raphé 5-HT neurones in vivo. Naunyn-Schmiedeberg's Arch Pharmacol 2000; 362: 41-45.
164. Yin R, French ED. A comparison of the effects of nicotine on dopamine and non-dopamine neurons in the rat ventral tegmental area: An in vitro electrophysiological study. Brain Res Bull 2000; 51: 507-514.
165. Wonnacott S, Irons J, Rapier C, Thorne B, Lunt GG. Presynaptic modulation of transmitter release by nicotinic receptors. Prog Brain Res 1989; 79: 157-163.
166. Bianchi C, Ferraro L, Tanganelli S, Morari M, Spalluto G, Simonato M, et al. 5-Hydroxytryptamine-mediated effects of nicotine on endogenoeus GABA efflux from guinea-pig cortical slices. Br J Pharmacol 1995; 116: 2724-2728.
167. Lu Y, Grady S, Marks MJ, Picciotto M, Changeux J-P, Collins AC. Pharmacological characterization of nicotinic receptor-stimulated GABA release from mouse brain synaptosomes. J Pharmacol Exp Ther 1998; 287: 648-657.
168. Hugues JR, Hatsukami DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among sychiatric outpatients. Am J Psychiatry 1986; 143: 993-997.
169. Poirier M-F, Canceil O, Baylé F, Millet B, Bourdel M-C, Moatti C, et al. Prevalence of smoking in psychiatric patients. Progr Neuropsychopharmacol Biol Psychiatry 2002; 26: 529-537.
170. Gilbert DG, Gilbert BO. Personality, psychopathology, and nicotine response as mediators of the genetics of smoking. Behav Genet 1995; 25: 133-147.
171. Van Ammers EC, Sellman JD, Mulder RT. Temperament and substance abuse in schizophrenia: Is there a relationship? J Nerv Ment Dis 1997; 185: 283-288.
172. Goff DC, Henderson DC, Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 1992; 149: 1189-1194.
173. Dalack GW, Meador-Woodruff JH. Smoking, smoking withdrawal and schizophrenia: Case reports and a review of the literature. Schizophr Res 1996; 22: 133-141.
174. Levin ED, Wilson W, Rose JE, McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 1996; 15: 429-436.
175. Adler LE, Waldo AOM, Harris JG, Griffith J, Stevens K, Flach K, et al. Schizophrenia, sensory gating and nicotinic receptors. Schizophr Bull 1998; 24: 189-202.
176. McGhie A, Chapman JS. Disorders of attention and perception in early schizophrenia. Br J Med Psychol 1961; 34: 103-117.
177. Glassman AH. Psychiatry and cigarettes. Arch Gen Psychiatry 1998; 55: 692-693.
178. Arias HR, Bhumireddy P, Bouzat C. Molecular mechanisms and binding site locations for noncompetitive antagonists of nicotinic acetylcholine receptors. Int J Biochem Cell Biol 2006; 38: 1254-1276.
179. Anderson JE, Jorenby DE, Scott WJ, Fiore MC. Treating tobacco use and dependence: An evidence-based clinical practice guideline for tobacco cessation. Chest 2002; 121: 932-941.
180. Shahan TA, Bickel WK, Madden GJ, Badger GJ. Comparing the reinforcing efficacy of nicotine containing and de-nicotinized cigarettes: A behavioral economic analysis. Psychopharmacology 1999; 147: 210-216
181. Mucha RF, Geier A, Pauli P. Modulation of craving by cues having differential overlap with pharmacological effect: Evidence for cue approach in smokers and social drinkers. Psychopharmacology 1999; 147: 306-313.
182. Dols M, Willems B, van den Hout M, Bittoun R. Smokers can learn to influence their urge to smoke. Addic Behav 2000; 25: 103-108.
183. Cryan JF, Gasparini F, van Heeke G, Marku A. Non-nicotinic neuropharmacological strategies for nicotine dependence: Beyond bupropion. Drug Discov Today 2003; 8: 1025-34.
184. Ascher JA, Cole JO, Colin J-N, Feighner JP, Ferris RM, Fibiger HC, et al. Bupropion: A review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56: 395-401.
185. Murray RP, Voelker HT, Rakos RF, Nides MA, McCutcheon VJ, Bjornson W. Intervention for relapse to smoking: The Lung Health Study restart programs. Addict Behav 1997; 22: 281-286.
186. Hajek P, West R, Foulds J, Nilsson F, Burrows S, Meadow A. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and inhaler. Arch Intern Med 1999; 158: 2033-2038.
187. Paun D, Franze J. Breaking the smoking habit using cytisin containing "Tabex" tablets. Dtsch Gesundheitsw 1968; 23: 2088-2091.
188. Benndorf S, Scharfenberg G, Kempe G, Wendekamm R, Winkelvoss E. Smoking withdrawal treatment with Cytisin (Tabex). Results of a semi-annual survey of former smokers after 4 weeks of therapy. Dtsch Gesundheitsw 1970; 24: 774-776.
189. Stead LF, Hughes JR. Lobeline for smoking cessation. Cochrane Database Syst Rev 2000; (2): CD000124.
190. 2 nicotinic receptor agonist with potential as an aid to smoking cessation. J Pharmacol Exp Ther 2003; 306: 407-420.
191. 2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005; 148: 3474-3477.
192. Crooks PA, Ayers JT, Xu R, Sumithran SP, Grinevich VP, Wilkins LH, Deaciuc AG, Allen DD, Dwoskin LP. Development of subtype-selective ligands as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release. Bioorg Med Chem Lett 2004; 14: 1869-1874.
193. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist J Pharmacol Exp Ther 2000; 295: 321-327.
194. Cooper BR, Wang CM, Cox RF, Norton R, Shea V, Ferris RM. Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology 1994; 11:133-141.
195. Ferris RM, Cooper BR. Mechanism of antidepressant activity of bupropion. J Clin Psychiatry Monograph 1993; 11: 2-14.
196. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337: 1195-202.
197. Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation: A randomized, controlled trial. Ann Intern Med 2001; 135: 423-433.
198. Sweet M. GlaxoSmithKline takes legal action to block new controls on its smoking cessation drug. Br Med J 2003; 326: 952.
199. Rose JE, Behm FM, Westman EC, Levin ED, Stein RM, Ripka GV. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin Pharmacol Ther 1994; 56: 86-99.
200. Rose JE, Behm FM, Westman EC. Nicotine-mecamylamine treatment for smoking cessation: The role of pre-cessation therapy. Exp Clin Psychopharmacol 1998; 6: 331-343.
201. Hall SM, Humfleet GL, Reus VI, Munoz RF, Hartz DT, Maude-Griffin R. Psychological intervention and antidepressant treatment in smoking cessation. Arch Gen Psychiatry 2002; 59: 930-936.
202. Edwards NB, Murphy JK, Downs AD, Ackerman BJ, Rosenthal TL. Doxepin as an adjunct to smoking cessation: A double-blind pilot study. Am J Psychiatry 1989; 146: 373-376.
203. Dalack GW, Glassman AH, Rivelli S, Covey L, Stetner F. Mood, major depression, and fluoxetine response in cigarette smokers. Am J Psychiatry 1995; 152: 398-403.
204. Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ, Cornelius MD, Black A, et al. Double-blind fluoxetine in depressed alcoholic smokers. Psychopharmacol Bull 1997; 33: 165-170.
205. Blondal T, Gudmundsson LJ, Tomasson K, Jonsdottir D, Hilmarsdottir H, Kristjansson F, et al. The effects of fluoxetine combined with nicotine inhalers in smoking cessation - a randomized trial. Addiction 1999; 94: 1007-1015.
206. Schneider NG, Olmstead RE, Steinberg C, Sloan K, Daims RM, Brown HV. Efficacy of buspirone in smoking cessation: A placebo-controlled trial. Clin Pharmacol Ther 1996; 60: 568-575.
207. Berlin I, Said S, Spreux-Varoquaux O, Launay JM, Olivares R, Millet V, et al. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin Pharmacol Ther 1995; 58: 444-452.
208. Gourlay SG, Benowitz NL. Is clonidine an effective smoking cessation tharapy? Drugs 1995; 50: 197-207.
209. Glassman AH, Jackson WK, Walsh BT, Roose SP, Rosenfeld B. Cigarette craving, smoking withdrawal, and clonidine. Science 1984; 226: 864-866.
210. Glassman AH, Covey LS, Dalack GW, Stetner F, Rivelli SK, Fleiss J, et al. Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. Clin Pharmacol Ther 1993; 54: 670-679.
211. Martin BR, Onaivi ES, Martin TJ. What is the nature of mecamylamine's antagonism of the central effects of nicotine? Biochem Pharmacol 1989; 38: 3391-3397.
212. Takayama H, Majewska MD, London ED. Interactions of noncompetitive inhibitors with nicotinic receptors in the rat brain. J Pharmacol Exp Ther 1989; 251: 1083-1089.
213. Stolerman IP. Could nicotine antagonists be used in smoking cessation? Br J Addict 1986; 81: 47-53.
214. Nemeth-Coslett R, Henningfield JE, O'Keeffe MK, Griffiths RR. Effects of mecamylamine on human cigarette smoking and subjective ratings. Psychopharmacology 1986; 88: 420-425.
215. Stolerman IP, Goldfarb T, Fink R, Jarvik ME. Unfluencing cigarette smoking with nicotine antagonists. Psychopharmacologia 1973; 28: 247-259.
216. Lundahl LH, Henningfield JE, Lukas SE. Mecamylamine blockade of both positive and negative effects of IV nicotine in human volunteers. Pharmacol Biochem Behav 2000; 66: 637-643.
217. Tennant FS Jr, Tarver AL, Rawson RA. Clinical evaluation of mecamylamine for withdrawal from nicotine dependence. NIDA Res Monogr 1984; 49: 239-246.
218. Collins AC, Luo Y, Selvaag S, Marks MJ. Sensitivity to nicotine and brain nicotinic receptors are altered by chronic nicotine and mecamylamine infusion. J Pharmacol Exp Ther 1994; 271: 125-133.
219. Eissenberg T, Griffiths RR, Stitzer ML. Mecamylamine does not precipitate withdrawal in cigarette smokers. Psychopharmacology 1996; 127: 328-336.
220. Pomerleau OF. Endogenous opioids and smoking: A review of progress and problems. Psychoneuroendocrinology 1998; 23: 115-130.
221. Krishnan-Sarin S, Rosen MI, O'Malley SS. Naloxone challenge in smokers. Preliminary evidence of an opioid component in nicotine dependence. Arch Gen Psychiatry 1999; 56: 663-668.
222. Sutherland G, Stapleton JA, Russell MA, Feyerabend C. Naltrexone, smoking behaviour and cigarette withdrawal. Psychopharmacology 1995; 120: 418-425.
223. Wong GY, Wolter TD, Croghan GA, Croghan IT, Offord KP, Hurt RD. A randomized trial of naltrexone for smoking cessation. Addiction 1999; 94: 1227-1237.
224. Cousins MS, Stamat HM, de Wit H. Effects of a single dose of baclofen on self-reported subjective effects and tobacco smoking. Nicotine Tob Res 2001; 3: 123-129.
225. 1 receptor antagonists for the treatment of nicotine addiction. Pharmacol Biochem Behav 2005; 81: 387-395.
226. Paterson NE, Semenova S, Gasparini F, Markou A. The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice. Psychopharmacology 2003; 167: 257-264.
227. Rasmussen K, Calligaro DO, Czachura JF, Dreshfield-Ahmad LJ, Evans DC, Hemrick-Luecke SK, et al. The novel 5-Hydroxytryptamine 1A antagonist LY426965: Effects on nicotine withdrawal and interactions with fluoxetine. J Pharmacol Exp Ther 2000; 294: 688-700.
228. Andreoli M, Tessari M, Pilla M, Valerio E, Hagan JJ, Heidbreder CA. Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior. Neuropsychopharmacology 2003; 28: 1272-1280.
229. Decker MW, Meyer MD, Sullivan JP. The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control. Expert Opin Investig Drugs 2001; 10: 1819-1830.
230. Fattore L, Cossu G, Martellotta MC, Fratta W. Baclofen antagonizes intravenous self-administration of nicotine in mice and rats. Alcohol Alcohol 2002; 37: 495-498.
231. Malin DH, Lake JR, Lin A, Saldana M, Balch L, Irvin ML, et al. Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome. Pharmacol Biochem Behav 2001; 68: 87-92.
232. Gatley, Volkow ND, Wang GJ, Fowler JS, Logan J, Ding YS, et al. PET imaging in clinical drug abuse research. Curr Pharm Des 2005; 11(25): 3203-19.
233. Gotti C, Riganti L, Vailati S, Clementi F. Brain neuronal nicotinic receptors as new targets for drug discovery. Curr Pharm Des 2006; 12(4): 407-28.
234. Leone A. Biochemical markers of cardiovascular damage from tobacco smoke. Curr Pharm Des 2005; 11(17): 2199-208.